Abbott

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

321

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 1

Gastroenterology

1100%

R&D Momentum

18/100

Pipeline Velocity

0/100

Trial Completion Rate

89/100

Pipeline Concentration

100/100

Pipeline Freshness

53/100

Activity

Key Events

Apr 1, 2025TrialStudy of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain

Jul 29, 2024FDAHytrin — TEZRULY

Feb 28, 2024TrialTrial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Jul 12, 2021TrialBio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects

Nov 27, 2020TrialEfficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

Oct 27, 2020TrialStudy to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)

Mar 3, 2020TrialPredictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines

Mar 27, 2019TrialBioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects

4 more events

Sep 27, 2018TrialStudy of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Aug 25, 2018TrialStudy to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea

Mar 29, 2018TrialControlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea

Jan 24, 2018TrialA Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

Hytrin2 patentsFeb 1, 2041

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gastroenterology

Dyspepsia

Itopride hydrochloride

Gastroenterology

Dyspepsia

Itopride hydrochloridePhase 3

Regulatory

Regulatory Timeline

19825 events

FDAJan 1

Cylert — CYLERT

Application NDA017703 (NDA)

FDAJan 1

Cylert — CYLERT

Application NDA016832 (NDA)

FDAJan 1

Coumadin — ATHROMBIN

Application NDA011771 (NDA)

FDAJan 1

Pentothal — PENTOTHAL

Application NDA011679 (NDA)

FDAJan 1

Coumadin — PANWARFIN

Application NDA017020 (NDA)

19861 event

FDAJun 3

Alka-Seltzer — SODIUM BICARBONATE IN PLASTIC CONTAINER

Application NDA019443 (NDA)

19871 event

FDAAug 7

Hytrin — HYTRIN

Application NDA019057 (NDA)

19901 event

FDADec 26

Prosom — PROSOM

Application NDA019080 (NDA)

19941 event

FDADec 14

Hytrin — HYTRIN

Application NDA020347 (NDA)

19951 event

FDAFeb 7

Coumadin — COUMADIN

Application NDA009218 (NDA)

19971 event

FDANov 22

Meridia — MERIDIA

Application NDA020632 (NDA)

20241 event

FDAJul 29

Hytrin — TEZRULY

Application NDA218139 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)